CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPOFOL	ADDITIONAL R	*USP39–NF34*	5573	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	EQUIREMENTS/*USP Reference Standards <11>*						*Supplement to USP40–NF35*	Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	REFERENCES	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of first reference: Delete http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx. AND Line 2 of second reference: Delete http://www.asco.org/advocacy/worker-safety-when-handling-hazardous-drugs-focus-statement-oncology-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								societies.
PERINDOPRIL ERBUMINE	CHEMICAL INFORMATION	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 9: Delete (2*S*,3a*S*,7a*S*)-1-{(*S*)-2-[(*R*)-1-Ethoxy-1-oxopentan-2-ylamino]propanoyl}octahydro-1*H*-indole-2-carboxylic acid
TRIHEXYPHENIDYL HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	*Assay*	*USP39–NF34*	6265	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine (920:80:0.2), adjust with phosphoric acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Procedure: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Trihexyphenidyl Hydrochloride*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 6 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP Trihexyphenidyl Hydrochloride RS in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
BISOCTRIZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Bisoctrizole Resolution Mixture RS: Change A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole. to: A mixture of approximately

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1.5% of bisoctrizole isomer [phenol, 2,2?-methylene bis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole.
ORALLY INHALED AND NASAL DRUG PRODUCTS	REFERENCES	*USP39–NF34*	1862	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete reference 3.
GRANISETRON HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	4153	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: *N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-y

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l]-1*H*-indazole-3-carboxamide.
LOVASTATIN	*USP Reference standards <11>*	*USP39–NF34*	4631	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Lovastatin Related Compound A RS: Change [Dihydro-lovastatin][butanoic acid, 2-methyl-, 1,2,3,4,4a,7,8,8a-octahydro-3,7-dimethyl-8-[2(tetrahydro-4-hydrox y-6-ox o-2*H*-pyran-2-yl)-eth yl]-1-naphthalen yl ester, [1*S*-[1?(*R**), 3?,7? ,8?(2*S**,4*S**),-8??]]]-. to: (1*S*,3*S*,4a*R*,7*S*,8*S*,8a*S*)-8-{2-[(2*R*,4*R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-4-hydroxy-6-ox ot etra hydro-2*H* -pyran-2-yl]ethyl }-3,7-dimethyl-1 ,2,3,4,4a,7,8,8a -octahydronapht halen-1-yl (*S*)-2-methylbutan oate.
SIMVASTATIN TABLETS	IM PUR ITIES/*Organic Impuri ties/Analysis*	*USP39–NF34*	5848	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change Result = (r_U/r_S) × (C_S/C_U) × (M_{r1}/M_{r2}) × 100 to: Result = (r_U/r_S) × (C_S/C_U)× 100 AND Delete the variable definitions for M_{r1} and M_{r2}.
FUMARIC ACID	SPECIFIC TESTS/*Water Determination, Method I <921>*	*USP39–NF34*	7309	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1: Change 0.5% to: NMT 0.5%
NAPROXEN SODIUM	IM PUR	*Second Supplement to*	Online	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to*	Line 6 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	ITIES/*Organic Impurities*	*USP39–NF34*					*USP40–NF35*	Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
EXTRACTABLES ASSOCIATED WITH PHARMACEUTICAL PACKAGING SYSTEMS	REFERENCES	*USP39–NF34*	1835	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete references 5, 7, 9, and 12.
FLUORESCEIN SODIUM	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3960	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 7 of column 1 of *Table 2*: Change Total impurities to: Total unspecified impurities
HALOPERIDOL DECANOATE	IMPURITIES/*Organic Impurities*/*Table 2*	*USP39–NF34*	4184	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Footnote k: Change 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. AND Footnote l: Change 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
RIZATRIPTAN BENZOATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/ Chromatographic procedure*	*USP39–NF34*	5750	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Add *Buffer*: 1.36 g/L of monobasic potassium phosphate. Adjust the pH of the solution with phosphoric acid to 2.5.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRIHEXYPHENIDYL HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP39–NF34*	6266	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and triethylamine (920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatography <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograms, and measure the responses for the major peaks. AND Line 7 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of USP Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SULINDAC TABLETS	IM PURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8160	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *System suitability/Relative standard deviation*: Change NMT 2.0% for any peak to: NMT 2.0% for sulindac, sulindac related compound B, and sulindac related compound C AND Line 3 of *Analysis*: Change Calculate the percentage of the labeled amount of sulindac related compound A, sulindac related compound B, or sulindac related compound C in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the portion of Tablets taken: to: Calculate the percentage of sulindac related compound B or sulindac related compound C in the portion of Tablets taken: AND Line 8 of *Analysis*: Change r_U = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Sample solution* to: r_U = peak response of sulindac related compound B or sulindac related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound C from the *Sample solution* AND Line 12 of *Analysis*: Change r_S = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Standard solution* to: r_S = peak response of sulindac related compound B or sulindac related compound C from the *Standard solution*
FELBAMATE ORAL SUSPENSION	PERFORMANCE TESTS/	*USP39–NF34*	3855	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 4 of *System suitability*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Dissolution <711>							Change [Note—The relative retention times for methylparaben and felbamate are about 0.5 and 1.0, respectively.] to: [Note—The relative retention times for felbamate and methylparaben are about 1.0 and 1.5, respectively.]
GRANISETRON HYDROCHLORIDE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	4155	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxamide). to: *N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide.
NAPROXEN TABLETS	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Tailing factor*: Change NLT 2.0 to: NMT 2.0
SODIUM NITROPRUSSIDE	*Identification*	*USP39–NF34*	5880	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Identification C*: Change A solution (1 in 4) responds to the flame test for *Sodium* <191>. to: A solution (1 in 4) imparts an intense yellow color to a nonluminous flame.
BISOCTRIZOL	IM	*First*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First*	Footnote b of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E	PUR ITIES/*Organic Impurities*	*Supplement to USP39–NF34*					*Supplement to USP40–NF35*	*Table 2*: Change Phenol, 2,2-met h yle nebis[6-(2*H* -benzotriazol-2-yl)-4-(1,1,3,3-tet ramethylbutyl)]. to: Phenol, 2,2?-m *H* -benzotriazol-2-yl)-4-(1,1,3,3-tet ramethylbutyl)].
ASSESSMENT OF DRUG PRODUCT LEACHABLES ASSOCIATED WITH PHARMA CEUTICAL PA CKAGING/DELI VERY SYSTEMS	REFERENCES	*USP39–NF34*	1850	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete reference 8.
GRANISETRO N HYDROCHL	*USP Reference standards <11>*	*USP39–NF34*	4151	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to*	Line 2 of USP Granisetron

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORIDE							*USP40–NF35*	Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: (*N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). AND Line 2 of USP Granisetron Related Compound E RS: Change ((1*R*,3*rS*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt). to: ((1*R*,3*r*,5*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-9-Methyl-9-azabicyclo[3.3.1]nonan-3-amine, acetate salt).
KETOROLAC TROMETHAMINE INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4468	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 4 of USP Ketorolac Related Compound A RS: Change 358.15 to: 358.39 AND Line 3 of USP Ketorolac Related Compound B RS: Change 227.09 to: 227.26 AND Line 3 of USP Ketorolac Related Compound C RS: Change 225.09 to: 225.24 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 3 of USP Ketorolac Related Compound D: Change 211.1 to: 211.3
SIMETHICONE	ASSAY/ *Procedure/Analysis*	*USP39–NF34*	5843	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Samples*: Change *Standard stock solution*, *Standard solution*, *Sample stock solution*, and *Sample solution* to: *Standard solution* and *Sample solution*
BANABA LEAF DRY EXTRACT	IDENTIFICATION	*USP39–NF34*	6494	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete *Identification A*. AND Line 1 of *Identification B*: Change *B.* to: *A.*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 1 of *Identification C*: Change *C.* to: *B.*
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/*Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters/Analysis*	*Second Supplement to USP39–NF34*	8755	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 16 of the third equation: Change *L* = label claim of total omega-3-acids ethyl esters (g/Capsule) to: *L* = label claim of total omega-3-acids ethyl esters (mg/Capsule)
FEXOFENADINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP39–NF34*	3895	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 7: Change [138452-21-8]. to: [153439-40-8].
HALCINONIDE CREAM	IM PUR ITIES/*Organic Impuri ties/ Chromatographi*	*USP39–NF34*	4176	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Column*: Change 1.8-µm packing L1 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	c system							1.7-µm packing L1
NAPROXEN TABLETS	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 6 of *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
SAMARIUM Sm 153 LEXIDRONAM INJECTION	*Other requirements*	*USP39–NF34*	5791	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1: Change *Injections and Implanted Drug Products <1>*; not subject to *Container Content*. to: Meets the requirements of *Injections and Implanted Drug Products <1>*; not subject to *Container content*.
CHONDROITIN SULFATE SODIUM, SHARK	COMPOSITION /*Disaccharide Composition*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Chondroitinase ABC solution*: Change 10.0 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Buffer solution to: 1.0 mL of *Buffer solution* AND Line 4 of *Analysis*: Change and 1.0 mL to: and 0.1 mL
SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS	IN VITRO PERFORMANCE TESTS	*USP39–NF34*	1869	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Application of Drug Release*: Change The individual amounts of drug released from *R* is plotted versus time, to: The individual amounts of drug released from *R* are plotted versus the square root of time,
SODIUM CETOSTEARYL SULFATE	IMPURITIES/*Limit of Sodium*	*USP39–NF34*	7518	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Endpoint detection*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Chloride and Sodium Sulfate/Sodium sulfate/ Titrimetric system							Change Potentiometric to: Visual
DICLOFENAC SODIUM EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3460	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change 0.001 mg/mL of USP Diclofenac Sodium RS in *Diluent* to: 0.001 mg/mL each of USP Diclofenac Sodium RS and USP Diclofenac Related Compound A RS in *Diluent*
LORAZEPAM TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards RS <11>*	*USP39–NF34*	4622	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{13}H_9Cl_2NO$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OXANDROLONE TABLETS	*Dissolution <711>/Test 3*	*USP39–NF34*	5193	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Chromatographic system*: Change 30-cm column to: 3-cm column
RANITIDINE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	5672	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N*-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-*N*-methyl-2-nitro-1,1-ethenediamine. to: *N*-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N ?-methyl-2-nitro -1,1-ethenedia mine.
CHONDROITIN SULFATE SODIUM, SHARK	IM PURITIES/*Limit of Protein*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change (See *Spectrophotom etry and Light-Scattering <851>*.) to: (See *Ultraviolet-Visible Spectroscopy <857>*.)
MYRISTYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7413	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution* AND Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*, and heat the solution in a sealed container in a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*
BACITRACIN ZINC	IMPURITIES	*USP39–NF34*	2674	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Delete the *Residue on Ignition <281>* test.
LORAZEPAM INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4620	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
NALTREXONE HYDROCHLORIDE	*Related compounds*	*USP39–NF34*	4985	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change $10F(C/W)(r_U / r_S)$ to: $1000F(C/W)(r$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{U}/r_{S}$)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RANITIDINE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5670	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth *N* ?-methyl-2-nitro-1,1-ethenediamine.
TETRACYCLINE HYDROCHLORIDE	ASSAY/ *Procedure*	*USP39–NF34*	6082	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 6 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								Change dilute with *Diluent* to volume. to: dilute with *Solution A* to volume.
VINPOCETINE	IMPURITIES/*Organic Impurities*	*USP39–NF34*	6880	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Footnote a of *Table 1*: Change Ethyl (12*RS*,13a*SR*,13b*SR*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(12*S*,13a*S*,13b*S*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). AND Footnoteb of *Table 1*: Change Methyl (13a*S*,13b*S*)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1*H*-in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dolo[3,2,1-*de*]pyrido[3,2,1-ij][1,5]naphthyridin e-12-carboxylat e (apovincamine). to: Methyl (13a*S*,13b*S*)-13a-ethyl-2,3, 5,6,13a,13b- hex ahydro -1*H* -in dolo[3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (apovincamine). AND Footnote d of *Table 1*: Change Ethyl (12*RS*,13a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS,13b*RS*)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (dihydrovinpocetine). to: Ethyl (12*R*,13a*S*,13b*S*)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxyla

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								te (dihydrovinpocetine).
REAGENTS, INDICATORS AND SOLUTIONS	REAGENTS/*6. General Tests for Reagents*/*6.2 Amino Nitrogen Test in Reagents*	*USP39–NF34*	2080	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	In the numerator of the equation: Change 2.8 to: 14 AND Add × *f* AND Line 10: Change where %LOD is the percentage of loss on drying. to: where *f* is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the percentage of loss on drying.
HAZARDOUS DRUGS—HAND	5. FACILITIES AND	*First Supplement to*	7721	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	First bullet in second

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LING IN HEALTHCARE SETTINGS	ENGINEERING CONTROLS/*5.3 Compounding*	*USP39–NF34*						paragraph: Change • Be externally vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented
IMIQUIMOD CREAM	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	4289	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Row 2 of Column 3 of *Table 2*: Change 1.5 to: 1.15 AND Row 3 of Column 3 of *Table 2*: Change 1.15 to: 1.5

Pagination

- First page « First
- Previous page ‹ Previous
- …

- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- Page 21
- …
- Next page Next ›
- Last page Last »